Legend Biotech (LEGN) drew investor attention after reporting second quarter 2026 earnings, with revenue of US$387.5 million and net income of US$33.2 million, compared with a loss in the prior year period.

The strong second quarter report and swing to net income appear to have helped Legend Biotech’s share price recover in the very short term, with a 1 day share price return of 5.66% and a 7 day share price return of 14.11%. However, the 1 year total shareholder return is still down 40.98% and the 3 year total shareholder return is down 67.39%, which signals that longer term momentum has been weak.

If Legend Biotech’s move has you reassessing opportunities in healthcare, it can be useful to compare it with other specialized treatment developers through a focused screener such as 43 healthcare AI stocks.

Given Legend Biotech’s sharp recent bounce but weak multi year returns, you now need to judge whether the latest earnings shift the story toward further potential upside or whether the stock has already priced in most of the good news.

Most Popular Narrative: 59.7% Undervalued

At a last close of $21.83 versus a narrative fair value of $54.23, Legend Biotech is framed as heavily undervalued, with that gap resting on specific growth and margin assumptions.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and CARTITUDE-6), and label updates that increase patient access, is setting up long-term revenue acceleration as the patient pool widens.

Want to see what underpins that kind of jump in fair value? The narrative leans on faster top line expansion, a swing to healthy margins, and a richer future earnings multiple. Curious which assumptions really move the model.

Legend Biotech is modeled on a future where its multiple myeloma franchise reaches more patients, operates with higher profitability, and commands a valuation multiple above the broader US biotechs sector. The gap between today’s share price and the narrative fair value reflects those expectations, not current profitability, so it is important for you to stress test each assumption against your own view of the company’s execution and competition.

Result: Fair Value of $54.23 (UNDERVALUED)

However, you also need to weigh key risks for Legend Biotech, including heavy reliance on CARVYKTI and rising competition that could affect its longer term outlook.

Next Steps

This mix of optimism and concern around Legend Biotech highlights how split sentiment can be. If you want to move quickly and form your own view based on both sides of the story, take a closer look at the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Legend Biotech?

If Legend Biotech has sharpened your focus, do not stop there. A broader watchlist can surface opportunities you would otherwise miss, especially when results arrive quickly.

• Spot potential undervalued opportunities early by scanning companies with strong fundamentals using the 49 high quality undervalued stocks.
• Prioritize resilience in uncertain conditions by focusing on companies with sturdy finances through the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for lesser known prospects with solid metrics before they gain wider attention using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.